

Peter G Rose

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1295366/peter-g-rose-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

224
papers

2,165
citations

27
h-index

44
g-index

239
ext. papers

2,574
ext. citations

3
avg, IF

4.86
L-index

| # | Paper | IF | Citations |
|-----|--|-----|-----------|
| 224 | Giant cell tumor of bone: risk factors for recurrence. <i>Clinical Orthopaedics and Related Research</i> , 2011 , 469, 591-9 | 2.2 | 234 |
| 223 | Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study. <i>Journal of Clinical Oncology</i> , 1999 , 17, 2676-80 | 2.2 | 181 |
| 222 | Metastatic patterns in histologic variants of ovarian cancer. An autopsy study. <i>Cancer</i> , 1989 , 64, 1508-13 | 6.4 | 180 |
| 221 | Nomograms Predicting Progression-Free Survival, Overall Survival, and Pelvic Recurrence in Locally Advanced Cervical Cancer Developed From an Analysis of Identifiable Prognostic Factors in Patients From NRG Oncology/Gynecologic Oncology Group Randomized Trials of Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2136-42 | 2.2 | 96 |
| 220 | Recurrent giant cell tumor of long bones: analysis of surgical management. <i>Clinical Orthopaedics and Related Research</i> , 2011 , 469, 1181-7 | 2.2 | 91 |
| 219 | Do surgical margin and local recurrence influence survival in soft tissue sarcomas?. <i>Clinical Orthopaedics and Related Research</i> , 2010 , 468, 3003-11 | 2.2 | 90 |
| 218 | A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2011 , 122, 111-5 | 4.9 | 86 |
| 217 | Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. <i>Journal of Clinical Oncology</i> , 2001 , 19, 2975-82 | 2.2 | 86 |
| 216 | Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?. <i>Gynecologic Oncology</i> , 2017 , 147, 85-91 | 4.9 | 49 |
| 215 | How Does the Level of Sacral Resection for Primary Malignant Bone Tumors Affect Physical and Mental Health, Pain, Mobility, Incontinence, and Sexual Function?. <i>Clinical Orthopaedics and Related Research</i> , 2016 , 474, 687-96 | 2.2 | 45 |
| 214 | Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2017 , 144, 459-467 | 4.9 | 45 |
| 213 | Surgical technique: Porous tantalum reconstruction for destructive nonprimary periacetabular tumors. <i>Clinical Orthopaedics and Related Research</i> , 2012 , 470, 594-601 | 2.2 | 42 |
| 212 | The value of preoperative biopsy in the management of solid presacral tumors. <i>Diseases of the Colon and Rectum</i> , 2013 , 56, 756-60 | 3.1 | 40 |
| 211 | A phase II trial of paclitaxel, carboplatin, and bevacizumab in advanced and recurrent endometrial carcinoma (EMCA). <i>Gynecologic Oncology</i> , 2015 , 136, 240-5 | 4.9 | 39 |
| 210 | Extended sacropelvic resection for locally recurrent rectal cancer: can it be done safely and with good oncologic outcomes?. <i>Diseases of the Colon and Rectum</i> , 2014 , 57, 47-55 | 3.1 | 38 |
| 209 | How Does the Level of Nerve Root Resection in En Bloc Sacrectomy Influence Patient-Reported Outcomes?. <i>Clinical Orthopaedics and Related Research</i> , 2017 , 475, 607-616 | 2.2 | 36 |
| 208 | A phase I trial of pegylated liposomal doxorubicin (PLD), carboplatin, bevacizumab and veliparib in recurrent, platinum-sensitive ovarian, primary peritoneal, and fallopian tube cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2016 , 140, 204-9 | 4.9 | 35 |

| | | | |
|-----|--|------|----|
| 207 | A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). <i>Gynecologic Oncology</i> , 2018 , 150, 247-252 | 4.9 | 35 |
| 206 | Tantalum acetabular cups provide secure fixation in THA after pelvic irradiation at minimum 5-year followup. <i>Clinical Orthopaedics and Related Research</i> , 2012 , 470, 3041-7 | 2.2 | 34 |
| 205 | A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma. <i>Gynecologic Oncology</i> , 2005 , 96, 296-300 | 4.9 | 34 |
| 204 | Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature. <i>Anticancer Research</i> , 2016 , 36, 6161-6164 | 2.3 | 34 |
| 203 | Acute encephalopathy due to aluminum toxicity successfully treated by combined intravenous deferoxamine and hemodialysis. <i>Journal of Clinical Pharmacology</i> , 2000 , 40, 296-300 | 2.9 | 33 |
| 202 | Management Strategies for Recurrent Endometrial Cancer. <i>Expert Review of Anticancer Therapy</i> , 2018 , 18, 873-885 | 3.5 | 33 |
| 201 | Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. <i>International Journal of Gynecological Cancer</i> , 2009 , 19, 1281-3 | 3.5 | 30 |
| 200 | Surgical management of 121 benign proximal fibula tumors. <i>Clinical Orthopaedics and Related Research</i> , 2010 , 468, 3056-62 | 2.2 | 30 |
| 199 | Outcomes and Complications of Reconstruction with Use of Free Vascularized Fibular Graft for Spinal and Pelvic Defects Following Resection of a Malignant Tumor. <i>Journal of Bone and Joint Surgery - Series A</i> , 2017 , 99, e69 | 5.6 | 28 |
| 198 | Sacral tumor resection: the effect of surgical staging on patient outcomes, resource management, and hospital cost. <i>Spine</i> , 2011 , 36, 1570-8 | 3.3 | 27 |
| 197 | Chemoradiotherapy: the new standard care for invasive cervical cancer. <i>Drugs</i> , 2000 , 60, 1239-44 | 12.1 | 25 |
| 196 | Is age a prognostic biomarker for survival among women with locally advanced cervical cancer treated with chemoradiation? An NRG Oncology/Gynecologic Oncology Group ancillary data analysis. <i>Gynecologic Oncology</i> , 2016 , 143, 294-301 | 4.9 | 24 |
| 195 | Recurrence patterns and survival endpoints in women with stage II uterine endometrioid carcinoma: a multi-institution study. <i>Gynecologic Oncology</i> , 2015 , 136, 235-9 | 4.9 | 20 |
| 194 | Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 452-458 | 3.5 | 18 |
| 193 | Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. <i>Obstetrics and Gynecology</i> , 2019 , 133, 245-254 | 4.9 | 17 |
| 192 | Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study. <i>Gynecologic Oncology</i> , 2015 , 136, 529-33 | 4.9 | 17 |
| 191 | Atypical Notochordal Cell Tumors: A Series of Notochordal-derived Tumors That Defy Current Classification Schemes. <i>American Journal of Surgical Pathology</i> , 2017 , 41, 39-48 | 6.7 | 16 |
| 190 | Racial disparity in the 30-day morbidity and mortality after surgery for endometrial cancer. <i>Gynecologic Oncology</i> , 2014 , 134, 510-5 | 4.9 | 14 |

| | | | |
|-----|---|-----|----|
| 189 | Activity of Bevacizumab in Patients With Low-Grade Serous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016 , 26, 1048-52 | 3.5 | 13 |
| 188 | Comparison of Porous Tantalum Acetabular Implants and Harrington Reconstruction for Metastatic Disease of the Acetabulum. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020 , 102, 1239-1247 | 5.6 | 13 |
| 187 | The impact of combined radiation and chemotherapy on outcome in uterine papillary serous carcinoma compared to chemotherapy alone. <i>Journal of Gynecologic Oncology</i> , 2016 , 27, e19 | 4 | 11 |
| 186 | A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology. <i>Gynecologic Oncology</i> , 2020 , 158, 794-802 | 4.9 | 10 |
| 185 | Morbidity and functional status of patients with pelvic neurogenic tumors after wide excision. <i>Clinical Orthopaedics and Related Research</i> , 2010 , 468, 2948-53 | 2.2 | 10 |
| 184 | Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , 2006 , 102, 236-9 | 4.9 | 10 |
| 183 | Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Mllerian cancer. <i>Gynecologic Oncology</i> , 2015 , 139, 407-12 | 4.9 | 9 |
| 182 | Referring survivors of endometrial cancer and complex atypical hyperplasia to bariatric specialists: a prospective cohort study. <i>American Journal of Obstetrics and Gynecology</i> , 2015 , 213, 350.e1-10 | 6.4 | 9 |
| 181 | Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer. <i>Journal of Ovarian Research</i> , 2019 , 12, 112 | 5.5 | 8 |
| 180 | Desensitization with oxaliplatin in patients intolerant of carboplatin desensitization. <i>International Journal of Gynecological Cancer</i> , 2014 , 24, 1603-6 | 3.5 | 7 |
| 179 | Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , 2007 , 104, 114-9 | 4.9 | 7 |
| 178 | Primary Melanoma of the Lung 2006 , 293-297 | | 7 |
| 177 | Use of prophylactic closed incision negative pressure therapy is associated with reduced surgical site infections in gynecologic oncology patients undergoing laparotomy. <i>American Journal of Obstetrics and Gynecology</i> , 2020 , 223, 731.e1-731.e9 | 6.4 | 7 |
| 176 | Impact of antibiotic treatment on immunotherapy response in women with recurrent gynecologic cancer. <i>Gynecologic Oncology</i> , 2021 , 161, 211-220 | 4.9 | 7 |
| 175 | Universal tolerance of nab-paclitaxel for gynecologic malignancies in patients with prior taxane hypersensitivity reactions. <i>Journal of Gynecologic Oncology</i> , 2017 , 28, e38 | 4 | 6 |
| 174 | Chordomas 2006 , 614-625 | | 6 |
| 173 | Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 159, 699-705 | 4.9 | 6 |
| 172 | Impact of intra-operative factors upon peri-operative outcomes in women undergoing hyperthermic intraperitoneal chemotherapy for gynecologic cancer. <i>Gynecologic Oncology</i> , 2021 , 161, 194-201 | 4.9 | 6 |

| | | | |
|-----|--|-----|---|
| 171 | Treatment of neuroendocrine carcinoma of the cervix with a PARP inhibitor based on next generation sequencing. <i>Gynecologic Oncology Reports</i> , 2019 , 30, 100499 | 1.3 | 5 |
| 170 | Large (36 or 40-mm) femoral heads decreased the rate of dislocation after revision total hip arthroplasty. <i>Journal of Bone and Joint Surgery - Series A</i> , 2012 , 94, 2095 | 5.6 | 5 |
| 169 | Signaling within the epithelial ovarian cancer tumor microenvironment: the challenge of tumor heterogeneity. <i>Annals of Translational Medicine</i> , 2020 , 8, 905 | 3.2 | 5 |
| 168 | Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021 , 161, 389-395 | 4.9 | 5 |
| 167 | Outcome of Sacropelvic Resection and Reconstruction Based on a Novel Classification System. <i>Journal of Bone and Joint Surgery - Series A</i> , 2020 , 102, 1956-1965 | 5.6 | 4 |
| 166 | Efficacy of Pegylated Liposomal Doxorubicin in Low-Grade Serous Ovarian Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2017 , 27, 907-911 | 3.5 | 4 |
| 165 | Evidence of extended (>7 years) activity of bevacizumab and metronomic cyclophosphamide in a patient with platinum-resistant low-grade serous ovarian carcinoma. <i>Anti-Cancer Drugs</i> , 2013 , 24, 986-8 | 2.4 | 4 |
| 164 | Stage IIB-IVA cancer of the cervix. <i>Cancer Journal (Sudbury, Mass)</i> , 2003 , 9, 404-14 | 2.2 | 4 |
| 163 | Undifferentiated endometrial carcinoma: a National Cancer Database analysis of prognostic factors and treatment outcomes. <i>International Journal of Gynecological Cancer</i> , 2019 , 29, 1126-1133 | 3.5 | 4 |
| 162 | Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021 , 50, 101844 | 1.9 | 4 |
| 161 | Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2021 , 160, 45-50 | 4.9 | 4 |
| 160 | High TGF-β signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition.. <i>Npj Precision Oncology</i> , 2021 , 5, 101 | 9.8 | 4 |
| 159 | Adverse post-operative outcomes in Jehovah's witnesses with gynecologic cancer within 30 days of surgery: A single institution review of 36 cases. <i>Gynecologic Oncology Reports</i> , 2017 , 22, 32-36 | 1.3 | 3 |
| 158 | Phyllodes Tumor of the Breast 2006 , 209-217 | | 3 |
| 157 | Impact of treatment modality on overall survival in women with advanced endometrial cancer: A National Cancer Database analysis. <i>Gynecologic Oncology</i> , 2021 , 160, 405-412 | 4.9 | 3 |
| 156 | Anastomotic leak following interval debulking surgery with or without hyperthermic intraperitoneal chemotherapy in women with advanced epithelial ovarian Cancer. <i>Gynecologic Oncology</i> , 2021 , 162, 645-651 | 4.9 | 3 |
| 155 | Efficacy and toxicity of prolonged pegylated liposomal doxorubicin use in women with recurrent epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020 , 158, 309-315 | 4.9 | 2 |
| 154 | Uncommon Cancers of the Bladder 2012 , 23-33 | | 2 |

| | | | |
|-----|---|-----|---|
| 153 | Germ Cell Tumors of the Ovary 2012 , 519-530 | | 2 |
| 152 | Phyllodes Tumor of the Breast 2012 , 243-256 | | 2 |
| 151 | Uncommon Tumors of the Kidney 2012 , 1-22 | | 2 |
| 150 | Rare Tumors of the Testis and Paratesticular Tissues 2012 , 77-96 | | 2 |
| 149 | Uncommon Cancers of the Prostate 2012 , 47-75 | | 2 |
| 148 | Cancer of the Small Bowel 2006 , 391-400 | | 2 |
| 147 | Atypical and Malignant Meningiomas 2006 , 639-648 | | 2 |
| 146 | Adenoid Cystic Carcinoma of the Breast 2006 , 187-193 | | 2 |
| 145 | Primary Sarcomas of the Lung 2006 , 264-278 | | 2 |
| 144 | Uncommon Cancers of the Bladder 2006 , 18-26 | | 2 |
| 143 | Incidence of squamous cell carcinomas of the head and neck following prolonged pegylated liposomal doxorubicin. <i>Anti-Cancer Drugs</i> , 2020 , 31, 747-750 | 2.4 | 2 |
| 142 | Exophytic Lumbar Vertebral Body Mass in an Adult with Back Pain. <i>American Journal of Neuroradiology</i> , 2020 , 41, 1786-1790 | 4.4 | 2 |
| 141 | Modified frailty index predicts postoperative complications in women with gynecologic cancer undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Gynecologic Oncology</i> , 2021 , 162, 368-374 | 4.9 | 2 |
| 140 | Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers. <i>Immunotherapy</i> , 2021 , 13, 1179-1192 | 3.8 | 2 |
| 139 | Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis 2012 , 647-658 | | 1 |
| 138 | Parathyroid Carcinoma 2012 , 201-209 | | 1 |
| 137 | Uncommon Tumors of the Esophagus 2012 , 373-388 | | 1 |
| 136 | Cancers of the Small Bowel 2012 , 441-451 | | 1 |

| | | |
|-----|---|---|
| 135 | Uncommon Adrenal Tumors in Children and Adolescents 2012 , 903-914 | 1 |
| 134 | Stromal Tumors of the Ovary 2012 , 507-518 | 1 |
| 133 | Chordomas 2012 , 721-732 | 1 |
| 132 | Uncommon Pediatric Brain Tumors 2006 , 798-809 | 1 |
| 131 | Urethral Cancer 2006 , 27-37 | 1 |
| 130 | Male Breast Cancer 2006 , 201-208 | 1 |
| 129 | Carcinoid Tumors of the Lung 2006 , 307-312 | 1 |
| 128 | Carcinosarcoma of the Breast 2006 , 218-229 | 1 |
| 127 | Uncommon Cancers of the Thyroid 2006 , 165-173 | 1 |
| 126 | Primary Lymphomas of the Lung 2006 , 257-263 | 1 |
| 125 | Uncommon Cancers of the Esophagus 2006 , 337-351 | 1 |
| 124 | Tubular Carcinoma 2006 , 230-235 | 1 |
| 123 | Uncommon Endocrine Tumors in Children and Adolescents 2006 , 775-797 | 1 |
| 122 | Gestational Trophoblastic Diseases 2006 , 532-542 | 1 |
| 121 | LangerhansSCell Histiocytosis of the Central Nervous System 2006 , 610-613 | 1 |
| 120 | Metaplastic Breast Carcinoma 2006 , 181-186 | 1 |
| 119 | Meningeal Sarcomas 2006 , 626-637 | 1 |
| 118 | Large Cell Neuroendocrine Carcinoma 2006 , 298-306 | 1 |

| | | | |
|-----|--|------|---|
| 117 | Rare Tumors of the Testis and Paratesticular Tissues 2006 , 66-85 | | 1 |
| 116 | Fallopian Tube Cancer 2006 , 477-484 | | 1 |
| 115 | Rare Tumors of the Larynx 2006 , 102-112 | | 1 |
| 114 | Primary Intracranial Germ Cell Tumors 2006 , 649-656 | | 1 |
| 113 | Small Cell Carcinomas of the Gastrointestinal Tract 2006 , 430-435 | | 1 |
| 112 | Landmark studies of therapeutic vaccination in cervical and ovarian cancers. <i>Lancet Oncology, The</i> , 2020 , 21, 1549-1550 | 21.7 | 1 |
| 111 | Pretreatment with LCK inhibitors chemosensitizes cisplatin-resistant endometrioid ovarian tumors. <i>Journal of Ovarian Research</i> , 2021 , 14, 55 | 5.5 | 1 |
| 110 | Perioperative outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in elderly women with epithelial ovarian cancer: analysis of a prospective registry. <i>International Journal of Gynecological Cancer</i> , 2021 , 31, 1021-1030 | 3.5 | 1 |
| 109 | Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing. <i>Anti-Cancer Drugs</i> , 2019 , 30, 636-639 | 2.4 | 1 |
| 108 | Rare Lymphomas 555-568 | | 1 |
| 107 | Seromuscular Colonic Flap for Intrapelvic Soft-Tissue Coverage: A Reconstructive Option for Plastic Surgeons When Traditionally Used Flaps Are Not Available. <i>Case Reports in Surgery</i> , 2015 , 2015, 563641 | 0.5 | 0 |
| 106 | Metaplastic Breast Carcinoma 2012 , 211-216 | | 0 |
| 105 | Tumors of the Vulva and Vagina 2012 , 587-599 | | 0 |
| 104 | Uncommon Cancers of the Stomach 2006 , 352-366 | | 0 |
| 103 | Efficacy of hyperthermic intraperitoneal chemotherapy and interval debulking surgery in women with advanced uterine serous carcinoma. <i>Gynecologic Oncology Reports</i> , 2021 , 38, 100876 | 1.3 | 0 |
| 102 | Team Approach: Oncologic Sacrectomy. <i>JBJS Reviews</i> , 2020 , 8, e1900226 | 2.6 | 0 |
| 101 | Surgical lymph node assessment influences adjuvant therapy in clinically apparent stage I endometrioid endometrial carcinoma, meeting Mayo criteria for lymphadenectomy. <i>Journal of Surgical Oncology</i> , 2021 , 123, 1292-1298 | 2.8 | 0 |
| 100 | Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma. <i>Gynecologic Oncology Reports</i> , 2021 , 37, 100840 | 1.3 | 0 |

- 99 Distal Femoral Subchondral Metastasis Mistaken for an Insufficiency Fracture and Treated with Total Knee Arthroplasty: A Case Report. *JBJS Case Connector*, **2014**, 4, e91 0.4
- 98 Combination of a fillet flap, free tissue transfer, and autologous tissue grafts in pelvic reconstruction following retroperitoneal sarcoma: a case report. *Microsurgery*, **2015**, 35, 320-3 2.1
- 97 Thymoma and Thymic Carcinoma **2012**, 279-301
- 96 Male Breast Cancer **2012**, 233-241
- 95 Glioma and Other Neuroepithelial Neoplasms **2012**, 767-794
- 94 Langerhans Cell Histiocytosis of the Central Nervous System **2012**, 715-720
- 93 Extraovarian Primary Peritoneal Carcinomas **2012**, 485-495
- 92 Fallopian Tube Cancer **2012**, 531-539
- 91 Gastrointestinal Stromal Tumors **2012**, 465-483
- 90 Borderline Tumors and Other Rare Epithelial Tumors of the Ovary **2012**, 497-506
- 89 Nasopharyngeal Carcinoma in Nonendemic Populations **2012**, 131-150
- 88 Adenoid Cystic Carcinoma of the Breast **2012**, 217-224
- 87 Large Cell Neuroendocrine Carcinoma **2012**, 343-353
- 86 Hematological Malignancies Uncommon Presentations of Plasma Cell Dyscrasias **2012**, 627-635
- 85 Atypical and Malignant Meningiomas **2012**, 733-745
- 84 Uncommon Cancers of the Stomach **2012**, 389-408
- 83 Uncommon Pediatric Brain Tumors **2012**, 927-942
- 82 Pineal Parenchymal Tumors **2012**, 813-821

- 81 Uncommon Pediatric Tumors of the Thorax **2012**, 877-901
- 80 Adrenal Neoplasms **2012**, 163-187
- 79 Uncommon Cancers of the Thyroid **2012**, 189-200
- 78 Non-Hodgkin Lymphoma of the Breast **2012**, 225-232
- 77 Carcinosarcoma of the Breast **2012**, 257-269
- 76 Tubular Carcinoma **2012**, 271-277
- 75 Primary Sarcomas of the Lung **2012**, 303-317
- 74 Mesotheliomas **2012**, 319-334
- 73 Primary Melanoma of the Lung **2012**, 335-341
- 72 Bronchioloalveolar Carcinoma of the Lung **2012**, 355-363
- 71 Primary Adenoid Cystic Carcinoma of the Lung **2012**, 365-372
- 70 Unusual Cancers of the Pancreas **2012**, 409-421
- 69 Urethral Cancer **2012**, 35-46
- 68 Uncommon Hepatobiliary Tumors **2012**, 423-440
- 67 Unusual Tumors of the Colon, Rectum, And Anus **2012**, 453-463
- 66 Tumors of the Cervix **2012**, 567-585
- 65 Rare Acute Leukemias **2012**, 601-609
- 64 Unusual Myelodysplastic Syndromes and Myeloproliferative Neoplasms **2012**, 613-616

- 63 Rare B Cell Lymphoproliferative Disorders **2012**, 617-626
- 62 Rare Bone Marrow Failure Conditions **2012**, 637-646
- 61 Uncommon Tumors of the Oral Cavity and Adjacent Structures **2012**, 97-117
- 60 Esthesioneuroblastoma **2012**, 151-162
- 59 Rare T Cell Lymphomas **2012**, 659-666
- 58 Unusual Cutaneous Malignancies **2012**, 667-683
- 57 Unusual Melanomas **2012**, 691-708
- 56 Primary Melanotic Tumors of the Central Nervous System **2012**, 709-714
- 55 Primary Central Nervous System Lymphoma **2012**, 747-757
- 54 Choroid Plexus Papilloma and Carcinoma **2012**, 759-766
- 53 Medulloblastoma in Adults **2012**, 795-811
- 52 Craniopharyngiomas **2012**, 823-834
- 51 Ophthalmic Cancers **2012**, 835-846
- 50 Introduction to Rare Cancers of Childhood **2012**, 847-849
- 49 Uncommon Tumors of the Gastrointestinal Tract in Children **2012**, 851-865
- 48 Rare Pediatric Malignancies of the Head And Neck **2012**, 867-875
- 47 Uncommon Pediatric Genitourinary Tumors **2012**, 915-926
- 46 Malignant Tumors of the Skin and Subcutaneous Tissue in Children **2012**, 943-957

- 45 Rare Tumors of the Larynx **2012**, 119-130
- 44 Esthesioneuroblastoma **2006**, 133-142
- 43 Uncommon Cancers of the Prostate **2006**, 38-65
- 42 Unusual Tumors of the Colon, Rectum and Anus **2006**, 401-409
- 41 Tumors of the Vulva and Vagina **2006**, 521-531
- 40 Tumors of the Cervix **2006**, 501-520
- 39 Primary Central Nervous System Lymphoma **2006**, 657-666
- 38 Mesotheliomas **2006**, 279-292
- 37 Bronchioloalveolar Carcinoma of the Lung **2006**, 313-320
- 36 Borderline Tumors and Other Rare Epithelial Tumors of the Ovary **2006**, 447-454
- 35 Germ Cell Tumors of the Ovary **2006**, 467-476
- 34 Mucoepidermoid Tumors of the Lung **2006**, 329-335
- 33 Uterine Sarcomas and Unusual Endometrial Carcinomas **2006**, 485-500
- 32 Uncommon Tumors of the Oral Cavity and Adjacent Structures **2006**, 87-101
- 31 Uncommon Tumors of the Gastrointestinal Tract in Children **2006**, 749-759
- 30 Uncommon Pediatric Genitourinary Tumors **2006**, 760-774
- 29 Nasopharyngeal Carcinoma in Non-endemic Populations **2006**, 113-132
- 28 Stromal Tumors of the Ovary **2006**, 455-466

27 Malignant Tumors of the Skin and Subcutaneous Tissue in Children **2006**, 810-818

26 Thymoma and Thymic Carcinoma **2006**, 237-256

25 Glioma and Other Neuroepithelial Neoplasms **2006**, 674-694

24 Uncommon Tumors of the Kidney **2006**, 1-17

23 Extra-ovarian Primary Peritoneal Carcinomas **2006**, 437-446

22 Choroid Plexus Papilloma and Carcinoma **2006**, 667-673

21 Neoplastic Disorders of the Adrenal Glands **2006**, 143-164

20 Uncommon Pediatric Tumors of the Thorax **2006**, 732-748

19 Craniopharyngiomas **2006**, 705-711

18 Primary Adenoid Cystic Carcinoma of the Lung **2006**, 321-328

17 Unusual Cutaneous Malignancies **2006**, 577-588

16 Melanotic Lesions of the Meninges **2006**, 605-609

15 Ophthalmic Cancers **2006**, 712-720

14 Non-Hodgkin Lymphoma of the Breast **2006**, 194-200

13 Unusual Pancreatic Tumors **2006**, 367-382

12 Cancer of the Appendix **2006**, 410-417

11 Gastrointestinal Stromal Tumors **2006**, 418-429

10 Rare Leukemias **2006**, 543-554

- 9 Uncommon Hepatobiliary Tumors **2006**, 383-390
- 8 Medulloblastoma and CNS Primitive Neuroectodermal Tumors **2006**, 695-704
- 7 Life or limb: an international qualitative study on decision making in sarcoma surgery during the COVID-19 pandemic. *BMJ Open*, **2021**, 11, e047175 3
- 6 Uncommon Presentations of Plasma Cell Dyscrasias 569-575
- 5 Rare Pediatric Malignancies of the Head and Neck 721-731
- 4 Posterior-First Two-Stage Approach to En Bloc Resection of Locally Recurrent Rectal Cancer Involving the Pelvic Sidewall. *Diseases of the Colon and Rectum*, **2021**, 64, e465-e470 3.1
- 3 Case Report: Circulating Tumor DNA Fraction Analysis Using Ultra-Low-Pass Whole-Genome Sequencing Correlates Response to Chemoradiation and Recurrence in Stage IV Small-Cell Carcinoma of the Cervix - A Longitudinal Study. *Frontiers in Oncology*, **2021**, 11, 652683 5.3
- 2 Development and validation of a comprehensive clinical risk-scoring model for prediction of overall survival in patients with endometrioid endometrial carcinoma. *Gynecologic Oncology*, **2021**, 163, 511-516^{4.9}
- 1 Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer.. *Gynecologic Oncology Reports*, **2022**, 40, 100951 1.3